Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2018 08:00 ET | Source: Fibrocell Science Inc

Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018

EXTON, Pa., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
December 11, 2017 16:01 ET | Source: Fibrocell Science Inc

Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering

EXTON, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
December 07, 2017 07:00 ET | Source: Fibrocell Science Inc

Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering

EXTON, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
November 13, 2017 08:00 ET | Source: Fibrocell Science Inc

Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights

EXTON, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
November 06, 2017 08:00 ET | Source: Fibrocell Science Inc

Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights

EXTON, Pa., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
October 02, 2017 16:30 ET | Source: Fibrocell Science, Inc.

Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa

EXTON, Pa., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that John Maslowski, President and Chief Executive Officer of Fibrocell, will present at 3:00 pm...
September 26, 2017 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

– FCX-007 well-tolerated through 12 weeks post-administration with encouraging safety and positive early trends noted in wound healing and pharmacology signals – – Data Safety Monitoring Board...
September 05, 2017 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy Summit

EXTON, Pa., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
August 09, 2017 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights

EXTON, Pa., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
August 03, 2017 08:00 ET | Source: Fibrocell Science, Inc.

Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference

EXTON, Pa., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...